plasma: MDS vs. CTR |
|
Mucin type O-Glycan biosynthesis |
9.77 × 10−15
|
Proteoglycans in cancer |
6.05 × 10−9
|
ErbB signaling pathway |
2.80 × 10−8
|
Ras signaling pathway |
2.02 × 10−7
|
Axon guidance |
2.02 × 10−5
|
Pathways in cancer |
2.02 × 10−5
|
Rap1 signaling pathway |
3.30 × 10−5
|
Lysine degradation |
3.33 × 10−5
|
Glioma |
6.23 × 10−5
|
Signaling pathways regulating pluripotency of stem cells |
9.51 × 10−5
|
EVs: MDS vs. CTR |
|
ECM-receptor interaction |
1.16 × 10−26
|
Fatty acid biosynthesis |
1.41 × 10−8
|
ErbB signaling pathway |
1.41 × 10−8
|
Proteoglycans in cancer |
1.57 × 10−8
|
Axon guidance |
3.54 × 10−8
|
Glioma |
5.42 × 10−8
|
Mucin type O-Glycan biosynthesis |
5.18 × 10−6
|
Estrogen signaling pathway |
3.52 × 10−5
|
Focal adhesion |
5.71 × 10−5
|
Signaling pathways regulating pluripotency of stem cells |
5.71 × 10−5
|
plasma: early vs. advanced MDS |
|
Amphetamine addiction |
1.56 × 10−7
|
Signaling pathways regulating pluripotency of stem cells |
5.60 × 10−6
|
Transcriptional misregulation in cancer |
1.35 × 10−5
|
Gap junction |
2.31 × 10−5
|
Glioma |
3.38 × 10−5
|
FoxO signaling pathway |
5.34 × 10−5
|
Hippo signaling pathway |
1.16 × 10−4
|
ErbB signaling pathway |
1.72 × 10−4
|
Proteoglycans in cancer |
1.75 × 10−4
|
TGF-beta signaling pathway |
2.54 × 10−4
|
EVs: early vs. advanced MDS |
|
Biotin metabolism |
7.16 × 10−3
|
Central carbon metabolism in cancer |
7.16 × 10−3
|
Signaling pathways regulating pluripotency of stem cells |
7.16 × 10−3
|
Lysine degradation |
9.83 × 10−3
|
TGF-beta signaling pathway |
9.83 × 10−3
|
Steroid biosynthesis |
1.29 × 10−2
|
Glioma |
1.39 × 10−2
|
RNA transport |
1.41 × 10−2
|
ErbB signaling pathway |
1.45 × 10−2
|
Morphine addiction |
1.45 × 10−2
|